Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Significant Increase in Short Interest

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 40,500 shares, a growth of 163.0% from the September 30th total of 15,400 shares. Based on an average daily volume of 12,300 shares, the days-to-cover ratio is presently 3.3 days. Approximately 0.5% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Cumberland Pharmaceuticals in a report on Friday. They set a “hold” rating for the company.

Cumberland Pharmaceuticals Stock Performance

Shares of CPIX stock opened at $1.21 on Friday. Cumberland Pharmaceuticals has a 12-month low of $1.19 and a 12-month high of $2.36. The firm has a market capitalization of $17.17 million, a price-to-earnings ratio of -2.05 and a beta of 0.20. The business has a 50 day simple moving average of $1.29 and a 200 day simple moving average of $1.44. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.44 and a quick ratio of 1.26.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.